A Phase 1 Single and Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 in Healthy Volunteers and Multiple Sclerosis Subjects

Status:
Not yet recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

This is a first-in-human, two-part, Phase 1 study that will characterize the safety, tolerability, PK, and immunogenicity of HuL001.

Phase 1

HuniLife Biotechnology, Inc.

Antibodies, Monoclonal